The path forward for Apotex is uncertain following the sudden death of founder and chairman Barry Sherman, who was the architect of the generic drugmaker’s litigation-heavy strategy.
[Read More …]
Less BS, More Facts, Some Opinions
The path forward for Apotex is uncertain following the sudden death of founder and chairman Barry Sherman, who was the architect of the generic drugmaker’s litigation-heavy strategy.
[Read More …]